Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Pozelimab

Aliases
REGN3918

10 clinical trials

5 indications

Indication
Paroxysmal Nocturnal Hemoglobinuria
Indication
Myasthenia Gravis
Indication
CD55 Deficient Protein Losing Enteropathy
Indication
CD55-deficient protein-losing enteropathy
Indication
CHAPLE
Clinical trial
A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy
Status: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Symptomatic Generalized Myasthenia Gravis
Status: Recruiting, Estimated PCD: 2025-08-29
Clinical trial
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria
Status: Recruiting, Estimated PCD: 2029-05-23
Clinical trial
An Expanded Access Program of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria
Status:
Clinical trial
An Open-Label, Expanded Access Program of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)
Status:
Clinical trial
A Randomized, Open-Label, Eculizumab and Ravulizumab Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Currently Treated With Eculizumab or Ravulizumab
Status: Terminated, Estimated PCD: 2023-07-12
Clinical trial
A Single Arm, Open-Label Study to Assess the Safety, Efficacy, and Pharmacodynamic Effects of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy
Status: Completed, Estimated PCD: 2022-05-05
Clinical trial
R3918-Pozelimab
Status:
Clinical trial
An Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)
Status: Active (not recruiting), Estimated PCD: 2021-11-09
Clinical trial
A Randomized, Open-label, Two-arm Study to Evaluate the Safety, Efficacy, and Pharmacodynamic Effects of Pozelimab and Cemdisiran Combination Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy
Status: Completed, Estimated PCD: 2022-10-25